ID   BGAL_HUMAN              Reviewed;         677 AA.
AC   P16278; B2R7H8; B7Z6B0; P16279;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   10-MAY-2017, entry version 195.
DE   RecName: Full=Beta-galactosidase;
DE            EC=3.2.1.23;
DE   AltName: Full=Acid beta-galactosidase;
DE            Short=Lactase;
DE   AltName: Full=Elastin receptor 1;
DE   Flags: Precursor;
GN   Name=GLB1; Synonyms=ELNR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=3143362; DOI=10.1016/S0006-291X(88)80038-X;
RA   Oshima A., Tsuji A., Nagao Y., Sakuraba H., Suzuki Y.;
RT   "Cloning, sequencing, and expression of cDNA for human beta-
RT   galactosidase.";
RL   Biochem. Biophys. Res. Commun. 157:238-244(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PARTIAL PROTEIN
RP   SEQUENCE, AND VARIANT LEU-10.
RC   TISSUE=Testis;
RX   PubMed=2511208;
RA   Morreau H., Galjart N.J., Gillemans N., Willemsen R.,
RA   van der Horst G.T.J., D'Azzo A.;
RT   "Alternative splicing of beta-galactosidase mRNA generates the classic
RT   lysosomal enzyme and a beta-galactosidase-related protein.";
RL   J. Biol. Chem. 264:20655-20663(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-10.
RX   PubMed=2111707; DOI=10.1089/dna.1990.9.119;
RA   Yamamoto Y., Hake C.A., Martin B.M., Kretz K.A., Ahern-Rindell A.J.,
RA   Naylor S.L., Mudd M., O'Brien J.S.;
RT   "Isolation, characterization, and mapping of a human acid beta-
RT   galactosidase cDNA.";
RL   DNA Cell Biol. 9:119-127(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   LEU-10.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-10.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT CYS-521.
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-10.
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   DOMAIN ELASTIN/LAMININ BINDING.
RX   PubMed=8383699; DOI=10.1172/JCI116280;
RA   Hinek A., Rabinovitch M., Keeley F., Okamura-Oho Y., Callahan J.;
RT   "The 67-kD elastin/laminin-binding protein is related to an
RT   enzymatically inactive, alternatively spliced form of beta-
RT   galactosidase.";
RL   J. Clin. Invest. 91:1198-1205(1993).
RN   [9]
RP   FUNCTION (ISOFORM 2).
RX   PubMed=8922281;
RA   Hinek A.;
RT   "Biological roles of the non-integrin elastin/laminin receptor.";
RL   Biol. Chem. 377:471-480(1996).
RN   [10]
RP   IDENTITY OF BETA-GALACTOSIDASE-RELATED PROTEIN WITH EBP.
RX   PubMed=9497360; DOI=10.1074/jbc.273.11.6319;
RA   Privitera S., Prody C.A., Callahan J.W., Hinek A.;
RT   "The 67-kDa enzymatically inactive alternatively spliced variant of
RT   beta-galactosidase is identical to the elastin/laminin-binding
RT   protein.";
RL   J. Biol. Chem. 273:6319-6326(1998).
RN   [11]
RP   REVIEW.
RX   PubMed=10571006; DOI=10.1016/S0925-4439(99)00075-7;
RA   Callahan J.W.;
RT   "Molecular basis of GM1 gangliosidosis and Morquio disease, type B.
RT   Structure-function studies of lysosomal beta-galactosidase and the
RT   non-lysosomal beta-galactosidase-like protein.";
RL   Biochim. Biophys. Acta 1455:85-103(1999).
RN   [12]
RP   ELASTIC-FIBER ASSEMBLY STUDIES.
RX   PubMed=10841810; DOI=10.1086/302968;
RA   Hinek A., Zhang S., Smith A.C., Callahan J.W.;
RT   "Impaired elastic-fiber assembly by fibroblasts from patients with
RT   either Morquio B disease or infantile GM1-gangliosidosis is linked to
RT   deficiency in the 67-kD spliced variant of beta-galactosidase.";
RL   Am. J. Hum. Genet. 67:23-36(2000).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-464.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-464 AND ASN-555.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   VARIANTS MPS4B LEU-273; HIS-482 AND CYS-509, AND VARIANT GM1G1
RP   CYS-494.
RX   PubMed=1928092;
RA   Oshima A., Yoshida K., Shimmoto M., Fukuhara Y., Sakuraba H.,
RA   Suzuki Y.;
RT   "Human beta-galactosidase gene mutations in morquio B disease.";
RL   Am. J. Hum. Genet. 49:1091-1093(1991).
RN   [19]
RP   VARIANT GM1G1 CYS-49, VARIANT GM1G3 THR-51, AND VARIANT GM1G2 CYS-201.
RX   PubMed=1909089;
RA   Nishimoto J., Nanba E., Inui K., Okada S., Suzuki K.;
RT   "GM1-gangliosidosis (genetic beta-galactosidase deficiency):
RT   identification of four mutations in different clinical phenotypes
RT   among Japanese patients.";
RL   Am. J. Hum. Genet. 49:566-574(1991).
RN   [20]
RP   VARIANTS GM1G3 THR-51 AND GLN-457, VARIANTS GM1G1 ARG-123 AND CYS-316,
RP   AND VARIANT GM1G2 CYS-201.
RX   PubMed=1907800;
RA   Yoshida K., Oshima A., Shimmoto M., Fukuhara Y., Sakuraba H.,
RA   Yanagisawa N., Suzuki Y.;
RT   "Human beta-galactosidase gene mutations in GM1-gangliosidosis: a
RT   common mutation among Japanese adult/chronic cases.";
RL   Am. J. Hum. Genet. 49:435-442(1991).
RN   [21]
RP   VARIANT GM1G1 HIS-482.
RX   PubMed=1487238; DOI=10.1007/BF00220071;
RA   Mosna G., Fattore S., Tubiello G., Brocca S., Trubia M., Gianazza E.,
RA   Gatti R., Danesino C., Minelli A., Piantanida M.;
RT   "A homozygous missense arginine to histidine substitution at position
RT   482 of the beta-galactosidase in an Italian infantile GM1-
RT   gangliosidosis patient.";
RL   Hum. Genet. 90:247-250(1992).
RN   [22]
RP   VARIANTS GM1G1 CYS-208 AND ARG-578, AND VARIANTS GM1G2 HIS-590 AND
RP   GLY-632.
RX   PubMed=8213816;
RA   Boustany R.-M.N., Qian W.-H., Suzuki K.;
RT   "Mutations in acid beta-galactosidase cause GM1-gangliosidosis in
RT   American patients.";
RL   Am. J. Hum. Genet. 53:881-888(1993).
RN   [23]
RP   VARIANT GM1G3 MET-82.
RX   PubMed=8198123;
RA   Chakraborty S., Rafi M.A., Wenger D.A.;
RT   "Mutations in the lysosomal beta-galactosidase gene that cause the
RT   adult form of GM1 gangliosidosis.";
RL   Am. J. Hum. Genet. 54:1004-1013(1994).
RN   [24]
RP   VARIANTS GM1G1 SER-148 AND ALA-216, VARIANT GM1G3 TYR-214, AND VARIANT
RP   GLY-532.
RA   Hilson W.L., Okamura-Oho Y., Zhang S., Clarke J.T.R., Mahuran D.,
RA   Callahan J.W.;
RT   "Novel missense mutations in beta-galactosidase that result in GM1-
RT   gangliosidosis.";
RL   Am. J. Hum. Genet. 55:A223-A223(1994).
RN   [25]
RP   VARIANTS MPS4B HIS-83 AND CYS-482.
RX   PubMed=7586649;
RA   Ishii N., Oohira T., Oshima A., Sakuraba H., Endo F., Matsuda I.,
RA   Sukegawa K., Orii T., Suzuki Y.;
RT   "Clinical and molecular analysis of a Japanese boy with Morquio B
RT   disease.";
RL   Clin. Genet. 48:103-108(1995).
RN   [26]
RP   VARIANT GM1G3 SER-263.
RA   Suzuki Y., Sakuraba H., Oshima A.;
RT   "Beta-galactosidase deficiency (beta-galactosidosis): GM1
RT   gangliosidosis and Morquio B disease.";
RL   (In) Scriver C.R., Beaudet A.L., Sly W.S., Valle D. (eds.);
RL   The metabolic and molecular bases of inherited disease, pp.2787-2823,
RL   McGraw-Hill Publishing Co., New York (1995).
RN   [27]
RP   VARIANTS GM1G1 HIS-59; ASN-591 AND CYS-591.
RA   Morrone A., Bardelli T., Donati M.A., Giorgi M., Di Rocco R.,
RA   Gatti R., Taddeucci G., Ricci R., D'Azzo A., Zammarchi E.;
RT   "Identification of new mutations in six Italian patients affected by a
RT   variant form of infantile GM1-gangliosidosis with severe
RT   cardiomyopathy.";
RL   Am. J. Hum. Genet. 61:A258-A258(1997).
RN   [28]
RP   VARIANTS SLOWLY PROGRESSIVE GM1-GANGLIOSIDOSIS HIS-201; SER-266 AND
RP   CYS-509.
RX   PubMed=9203065; DOI=10.1177/088307389701200404;
RA   Kaye E.M., Shalish C., Livermore J., Taylor H.A., Stevenson R.E.,
RA   Breakefield X.O.;
RT   "Beta-Galactosidase gene mutations in patients with slowly progressive
RT   GM1 gangliosidosis.";
RL   J. Child Neurol. 12:242-247(1997).
RN   [29]
RP   VARIANTS MPS4B GLU-438; LYS-484 AND ALA-500.
RX   PubMed=12393180; DOI=10.1016/S0925-4439(02)00172-2;
RA   Bagshaw R.D., Zhang S., Hinek A., Skomorowski M.-A., Whelan D.,
RA   Clarke J.T.R., Callahan J.W.;
RT   "Novel mutations (Asn 484 Lys, Thr 500 Ala, Gly 438 Glu) in Morquio B
RT   disease.";
RL   Biochim. Biophys. Acta 1588:247-253(2002).
RN   [30]
RP   VARIANTS GM1G1 HIS-59; SER-121; CYS-208; MET-240 AND ASN-491, AND
RP   VARIANTS LEU-10; CYS-521 AND GLY-532.
RX   PubMed=10338095;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<401::AID-HUMU9>3.0.CO;2-N;
RA   Silva C.M.D., Severini M.H., Sopelsa A., Coelho J.C., Zaha A.,
RA   d'Azzo A., Giugliani R.;
RT   "Six novel beta-galactosidase gene mutations in Brazilian patients
RT   with GM1-gangliosidosis.";
RL   Hum. Mutat. 13:401-409(1999).
RN   [31]
RP   VARIANTS GM1G1 SER-148 AND ASN-332, VARIANT GLY-532, AND
RP   CHARACTERIZATION OF VARIANT GLY-532.
RX   PubMed=10839995; DOI=10.1042/bj3480621;
RA   Zhang S., Bagshaw R., Hilson W., Oho Y., Hinek A., Clarke J.T.R.,
RA   Hinek A., Callahan J.W.;
RT   "Characterization of beta-galactosidase mutations Asp332-->Asn and
RT   Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1
RT   gangliosidosis.";
RL   Biochem. J. 348:621-632(2000).
RN   [32]
RP   VARIANTS GM1G1 HIS-59; HIS-482; ASN-591 AND CYS-591, AND VARIANTS
RP   GM1G2 HIS-201 AND ASP-579.
RX   PubMed=10737981;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<354::AID-HUMU8>3.0.CO;2-L;
RA   Morrone A., Bardelli T., Donati M.A., Giorgi M., Di Rocco M.,
RA   Gatti R., Parini R., Ricci R., Taddeucci G., D'Azzo A., Zammarchi E.;
RT   "Beta-galactosidase gene mutations affecting the lysosomal enzyme and
RT   the elastin-binding protein in GM1-gangliosidosis patients with
RT   cardiac involvement.";
RL   Hum. Mutat. 15:354-366(2000).
RN   [33]
RP   VARIANTS MPS4B LEU-273; PRO-408 AND ALA-500, VARIANTS GM1G3 MET-82;
RP   ASP-270 AND TYR-281, AND VARIANT LEU-10.
RX   PubMed=11511921; DOI=10.1007/s004390100570;
RA   Paschke E., Milos I., Kreimer-Erlacher H., Hoefler G., Beck M.,
RA   Hoeltzenbein M., Kleijer W., Levade T., Michelakakis H., Radeva B.;
RT   "Mutation analyses in 17 patients with deficiency in acid beta-
RT   galactosidase: three novel point mutations and high correlation of
RT   mutation W273L with Morquio disease type B.";
RL   Hum. Genet. 109:159-166(2001).
RN   [34]
RP   VARIANTS GM1G2 TRP-68 AND CYS-201, CHARACTERIZATION OF VARIANTS GM1G2
RP   TRP-68 AND CYS-201, VARIANT PHE-436, AND MODULATING ACTION OF VARIANT
RP   PHE-436.
RX   PubMed=12644936; DOI=10.1007/s00439-003-0930-8;
RA   Caciotti A., Bardelli T., Cunningham J., D'Azzo A., Zammarchi E.,
RA   Morrone A.;
RT   "Modulating action of the new polymorphism L436F detected in the GLB1
RT   gene of a type-II GM1 gangliosidosis patient.";
RL   Hum. Genet. 113:44-50(2003).
RN   [35]
RP   VARIANT GM1G1 TYR-151, AND CHARACTERIZATION OF VARIANT GM1G1 TYR-151.
RX   PubMed=15365997; DOI=10.1002/humu.9279;
RA   Georgiou T., Drousiotou A., Campos Y., Caciotti A., Sztriha L.,
RA   Gururaj A., Ozand P., Zammarchi E., Morrone A., D'Azzo A.;
RT   "Four novel mutations in patients from the Middle East with the
RT   infantile form of GM1-gangliosidosis.";
RL   Hum. Mutat. 24:352-352(2004).
RN   [36]
RP   ERRATUM.
RA   Georgiou T., Drousiotou A., Campos Y., Caciotti A., Sztriha L.,
RA   Gururaj A., Ozand P., Zammarchi E., Morrone A., D'Azzo A.;
RL   Hum. Mutat. 24:536-537(2004).
RN   [37]
RP   VARIANTS GM1G1 HIS-59; CYS-59; CYS-208; MET-239; TYR-281; HIS-482;
RP   ASP-579; ASN-591 AND CYS-591, VARIANT GM1G2 HIS-201, VARIANT CYS-521,
RP   CHARACTERIZATION OF VARIANTS GM1G1 HIS-59; CYS-59; CYS-208; MET-239;
RP   TYR-281; HIS-482; ASP-579; ASN-591 AND CYS-591, CHARACTERIZATION OF
RP   VARIANT GM1G2 HIS-201, AND CHARACTERIZATION OF VARIANT CYS-521.
RX   PubMed=15714521; DOI=10.1002/humu.20147;
RA   Caciotti A., Donati M.A., Boneh A., d'Azzo A., Federico A., Parini R.,
RA   Antuzzi D., Bardelli T., Nosi D., Kimonis V., Zammarchi E.,
RA   Morrone A.;
RT   "Role of beta-galactosidase and elastin binding protein in lysosomal
RT   and nonlysosomal complexes of patients with GM1-gangliosidosis.";
RL   Hum. Mutat. 25:285-292(2005).
RN   [38]
RP   VARIANTS GM1G1 LEU-10 AND TYR-151.
RX   PubMed=15791924;
RA   Gururaj A., Sztriha L., Hertecant J., Johansen J.G., Georgiou T.,
RA   Campos Y., Drousiotou A., d'Azzo A.;
RT   "Magnetic resonance imaging findings and novel mutations in GM1
RT   gangliosidosis.";
RL   J. Child Neurol. 20:57-60(2005).
RN   [39]
RP   VARIANTS GM1G3 HIS-49; GLU-73; CYS-148 AND GLU-438.
RX   PubMed=15986423; DOI=10.1002/mds.20593;
RA   Roze E., Paschke E., Lopez N., Eck T., Yoshida K., Maurel-Ollivier A.,
RA   Doummar D., Caillaud C., Galanaud D., Billette de Villemeur T.,
RA   Vidailhet M., Roubergue A.;
RT   "Dystonia and parkinsonism in GM1 type 3 gangliosidosis.";
RL   Mov. Disord. 20:1366-1369(2005).
RN   [40]
RP   VARIANTS GM1G1 CYS-59; HIS-59; SER-136; VAL-151; PRO-173; CYS-199;
RP   ASP-272; ASN-346; CYS-347; PRO-420; ARG-422; ASN-441 AND CYS-590,
RP   VARIANT GM1G2 SER-264, VARIANTS GM1G3 HIS-201 AND LYS-420, VARIANTS
RP   MPS4B CYS-83; CYS-444; SER-494 AND ALA-500, AND VARIANTS PHE-436;
RP   CYS-521 AND GLY-532.
RX   PubMed=16941474; DOI=10.1002/humu.9451;
RA   Santamaria R., Chabas A., Coll M.J., Miranda C.S., Vilageliu L.,
RA   Grinberg D.;
RT   "Twenty-one novel mutations in the GLB1 gene identified in a large
RT   group of GM1-gangliosidosis and Morquio B patients: possible common
RT   origin for the prevalent p.R59H mutation among Gypsies.";
RL   Hum. Mutat. 27:1060-1060(2006).
RN   [41]
RP   VARIANTS MPS4B LEU-273; HIS-482 AND CYS-509, AND VARIANTS GM1G1
RP   CYS-201; HIS-201 AND HIS-318.
RX   PubMed=16538002; DOI=10.2152/jmi.53.103;
RA   Tatano Y., Takeuchi N., Kuwahara J., Sakuraba H., Takahashi T.,
RA   Takada G., Itoh K.;
RT   "Elastogenesis in cultured dermal fibroblasts from patients with
RT   lysosomal beta-galactosidase, protective protein/cathepsin A and
RT   neuraminidase-1 deficiencies.";
RL   J. Med. Invest. 53:103-112(2006).
RN   [42]
RP   VARIANTS GM1G1 CYS-59; HIS-59; VAL-134; LEU-147 DEL; SER-162; CYS-208;
RP   ASP-272; 377-VAL--LYS-381 DEL; TYR-491; LEU-549 AND CYS-590, VARIANT
RP   GM1G2 HIS-201, VARIANT GM1G3 ARG-155, AND VARIANTS GM1-GANGLIOSIDOSIS
RP   LEU-434 AND GLU-554.
RX   PubMed=17309651; DOI=10.1111/j.1399-0004.2007.00767.x;
RA   Santamaria R., Blanco M., Chabas A., Grinberg D., Vilageliu L.;
RT   "Identification of 14 novel GLB1 mutations, including five deletions,
RT   in 19 patients with GM1 gangliosidosis from South America.";
RL   Clin. Genet. 71:273-279(2007).
RN   [43]
RP   VARIANT TRP-595, AND CHARACTERIZATION OF VARIANT TRP-595.
RX   PubMed=17661814; DOI=10.1111/j.1399-0004.2007.00843.x;
RA   Gort L., Santamaria R., Grinberg D., Vilageliu L., Chabas A.;
RT   "Identification of a novel pseudodeficiency allele in the GLB1 gene in
RT   a carrier of GM1 gangliosidosis.";
RL   Clin. Genet. 72:109-111(2007).
RN   [44]
RP   CHARACTERIZATION OF VARIANTS GM1G1 HIS-59; SER-162; PRO-173; HIS-201;
RP   PRO-420; ASN-441; CYS-521 AND CYS-590, CHARACTERIZATION OF VARIANTS
RP   MPS4B CYS-83; CYS-444 AND SER-494, CHARACTERIZATION OF VARIANT GM1G3
RP   LYS-420, AND CHARACTERIZATION OF VARIANT GLY-532.
RX   PubMed=17664528; DOI=10.1194/jlr.M700308-JLR200;
RA   Santamaria R., Chabas A., Callahan J.W., Grinberg D., Vilageliu L.;
RT   "Expression and characterization of 14 GLB1 mutant alleles found in
RT   GM1-gangliosidosis and Morquio B patients.";
RL   J. Lipid Res. 48:2275-2282(2007).
RN   [45]
RP   VARIANTS GM1G1 HIS-59; THR-132; ARG-184; ASP-190; CYS-201; HIS-201;
RP   MET-239; HIS-255; ILE-329; GLU-332; ASN-346; GLN-442 AND SER-597,
RP   VARIANTS GM1G2 GLN-68; ARG-155 AND HIS-333, VARIANTS GM1G3 MET-82;
RP   ASP-270 AND GLU-438, VARIANTS MPS4B PHE-149; TYR-198; LEU-273;
RP   ALA-397; PRO-408 AND ALA-500, CHARACTERIZATION OF VARIANTS GM1G1
RP   THR-132; ARG-184; ASP-190; CYS-201; HIS-201; HIS-255; ILE-329; GLU-332
RP   AND SER-597, CHARACTERIZATION OF VARIANTS GM1G2 GLN-68; ARG-155 AND
RP   HIS-333, CHARACTERIZATION OF VARIANTS GM1G3 ASP-270 AND GLU-438, AND
RP   CHARACTERIZATION OF VARIANTS MPS4B PHE-149; TYR-198; LEU-273; ALA-397;
RP   PRO-408 AND ALA-500.
RX   PubMed=19472408; DOI=10.1002/humu.21031;
RA   Hofer D., Paul K., Fantur K., Beck M., Buerger F., Caillaud C.,
RA   Fumic K., Ledvinova J., Lugowska A., Michelakakis H., Radeva B.,
RA   Ramaswami U., Plecko B., Paschke E.;
RT   "GM1 gangliosidosis and Morquio B disease: expression analysis of
RT   missense mutations affecting the catalytic site of acid beta-
RT   galactosidase.";
RL   Hum. Mutat. 30:1214-1221(2009).
RN   [46]
RP   VARIANTS GM1G2 CYS-49; ARG-134; CYS-148; GLU-262; LEU-314; PRO-337;
RP   VAL-414; ASN-493; LEU-597 AND ILE-600, CHARACTERIZATION OF VARIANTS
RP   GM1G2 CYS-49; GLU-262; LEU-314; PRO-337; VAL-414; ASN-493; LEU-597 AND
RP   ILE-600, VARIANTS GM1G1 TRP-68; ARG-123; PRO-236; CYS-331; ASN-332;
RP   PRO-337; HIS-482 AND PRO-514, CHARACTERIZATION OF VARIANTS GM1G1
RP   TRP-68; ARG-123; PRO-236; ASN-332; PRO-337; HIS-482 AND PRO-514,
RP   VARIANT GM1G3 PHE-297, CHARACTERIZATION OF VARIANT GM1G3 PHE-297, AND
RP   VARIANTS GLN-129 AND CYS-521.
RX   PubMed=25936995; DOI=10.1016/j.gene.2015.04.078;
RA   Bidchol A.M., Dalal A., Trivedi R., Shukla A., Nampoothiri S.,
RA   Sankar V.H., Danda S., Gupta N., Kabra M., Hebbar S.A., Bhat R.Y.,
RA   Matta D., Ekbote A.V., Puri R.D., Phadke S.R., Gowrishankar K.,
RA   Aggarwal S., Ranganath P., Sharda S., Kamate M., Datar C.A., Bhat K.,
RA   Kamath N., Shah H., Krishna S., Gopinath P.M., Verma I.C.,
RA   Nagarajaram H.A., Satyamoorthy K., Girisha K.M.;
RT   "Recurrent and novel GLB1 mutations in India.";
RL   Gene 567:173-181(2015).
CC   -!- FUNCTION: Cleaves beta-linked terminal galactosyl residues from
CC       gangliosides, glycoproteins, and glycosaminoglycans.
CC   -!- FUNCTION: Isoform 2 has no beta-galactosidase catalytic activity,
CC       but plays functional roles in the formation of extracellular
CC       elastic fibers (elastogenesis) and in the development of
CC       connective tissue. Seems to be identical to the elastin-binding
CC       protein (EBP), a major component of the non-integrin cell surface
CC       receptor expressed on fibroblasts, smooth muscle cells,
CC       chondroblasts, leukocytes, and certain cancer cell types. In
CC       elastin producing cells, associates with tropoelastin
CC       intracellularly and functions as a recycling molecular chaperone
CC       which facilitates the secretions of tropoelastin and its assembly
CC       into elastic fibers.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal non-reducing beta-D-
CC       galactose residues in beta-D-galactosides.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Lysosome.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm, perinuclear region.
CC       Note=Localized to the perinuclear area of the cytoplasm but not to
CC       lysosomes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P16278-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta-galactosidase-related protein,
CC       Beta-galactosidase-like protein, S-Gal, Elastin-binding protein,
CC       EBP;
CC         IsoId=P16278-2, P16279-1;
CC         Sequence=VSP_031241;
CC       Name=3;
CC         IsoId=P16278-3; Sequence=VSP_039974;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: GM1-gangliosidosis 1 (GM1G1) [MIM:230500]: An autosomal
CC       recessive lysosomal storage disease marked by the accumulation of
CC       GM1 gangliosides, glycoproteins and keratan sulfate primarily in
CC       neurons of the central nervous system. GM1-gangliosidosis type 1
CC       is characterized by onset within the first three months of life,
CC       central nervous system degeneration, coarse facial features,
CC       hepatosplenomegaly, skeletal dysmorphology reminiscent of Hurler
CC       syndrome, and rapidly progressive psychomotor deterioration.
CC       Urinary oligosaccharide levels are high. It leads to death usually
CC       between the first and second year of life.
CC       {ECO:0000269|PubMed:10338095, ECO:0000269|PubMed:10737981,
CC       ECO:0000269|PubMed:10839995, ECO:0000269|PubMed:1487238,
CC       ECO:0000269|PubMed:15365997, ECO:0000269|PubMed:15714521,
CC       ECO:0000269|PubMed:15791924, ECO:0000269|PubMed:16538002,
CC       ECO:0000269|PubMed:16941474, ECO:0000269|PubMed:17309651,
CC       ECO:0000269|PubMed:17664528, ECO:0000269|PubMed:1907800,
CC       ECO:0000269|PubMed:1909089, ECO:0000269|PubMed:1928092,
CC       ECO:0000269|PubMed:19472408, ECO:0000269|PubMed:25936995,
CC       ECO:0000269|PubMed:8213816, ECO:0000269|Ref.24,
CC       ECO:0000269|Ref.27}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: GM1-gangliosidosis 2 (GM1G2) [MIM:230600]: A
CC       gangliosidosis characterized by onset between ages 1 and 5. The
CC       main symptom is locomotor ataxia, ultimately leading to a state of
CC       decerebration with epileptic seizures. Patients do not display the
CC       skeletal changes associated with the infantile form, but they
CC       nonetheless excrete elevated amounts of beta-linked galactose-
CC       terminal oligosaccharides. Inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:10737981, ECO:0000269|PubMed:12644936,
CC       ECO:0000269|PubMed:15714521, ECO:0000269|PubMed:16941474,
CC       ECO:0000269|PubMed:17309651, ECO:0000269|PubMed:1907800,
CC       ECO:0000269|PubMed:1909089, ECO:0000269|PubMed:19472408,
CC       ECO:0000269|PubMed:25936995, ECO:0000269|PubMed:8213816}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: GM1-gangliosidosis 3 (GM1G3) [MIM:230650]: A
CC       gangliosidosis with a variable phenotype. Patients show mild
CC       skeletal abnormalities, dysarthria, gait disturbance, dystonia and
CC       visual impairment. Visceromegaly is absent. Intellectual deficit
CC       can initially be mild or absent but progresses over time.
CC       Inheritance is autosomal recessive. {ECO:0000269|PubMed:11511921,
CC       ECO:0000269|PubMed:15986423, ECO:0000269|PubMed:16941474,
CC       ECO:0000269|PubMed:17309651, ECO:0000269|PubMed:17664528,
CC       ECO:0000269|PubMed:1907800, ECO:0000269|PubMed:1909089,
CC       ECO:0000269|PubMed:19472408, ECO:0000269|PubMed:25936995,
CC       ECO:0000269|PubMed:8198123, ECO:0000269|Ref.24,
CC       ECO:0000269|Ref.26}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mucopolysaccharidosis 4B (MPS4B) [MIM:253010]: A form of
CC       mucopolysaccharidosis type 4, an autosomal recessive lysosomal
CC       storage disease characterized by intracellular accumulation of
CC       keratan sulfate and chondroitin-6-sulfate. Key clinical features
CC       include short stature, skeletal dysplasia, dental anomalies, and
CC       corneal clouding. Intelligence is normal and there is no direct
CC       central nervous system involvement, although the skeletal changes
CC       may result in neurologic complications. There is variable
CC       severity, but patients with the severe phenotype usually do not
CC       survive past the second or third decade of life.
CC       {ECO:0000269|PubMed:11511921, ECO:0000269|PubMed:12393180,
CC       ECO:0000269|PubMed:16538002, ECO:0000269|PubMed:16941474,
CC       ECO:0000269|PubMed:17664528, ECO:0000269|PubMed:1928092,
CC       ECO:0000269|PubMed:19472408, ECO:0000269|PubMed:7586649}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 35 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Beta-galactosidase entry;
CC       URL="https://en.wikipedia.org/wiki/Beta-galactosidase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22590; AAA51822.1; -; mRNA.
DR   EMBL; M27507; AAA51819.1; -; mRNA.
DR   EMBL; M27508; AAA35599.1; -; mRNA.
DR   EMBL; M34423; AAA51823.1; -; mRNA.
DR   EMBL; AK300021; BAH13196.1; -; mRNA.
DR   EMBL; AK312988; BAG35825.1; -; mRNA.
DR   EMBL; BT007147; AAP35811.1; -; mRNA.
DR   EMBL; AC112211; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC007493; AAH07493.1; -; mRNA.
DR   CCDS; CCDS43061.1; -. [P16278-1]
DR   CCDS; CCDS43062.1; -. [P16278-3]
DR   CCDS; CCDS46785.1; -. [P16278-2]
DR   PIR; A32688; A32611.
DR   PIR; B32688; B32688.
DR   RefSeq; NP_000395.2; NM_000404.3. [P16278-1]
DR   RefSeq; NP_001073279.1; NM_001079811.2. [P16278-3]
DR   RefSeq; NP_001129074.1; NM_001135602.2. [P16278-2]
DR   RefSeq; NP_001303969.1; NM_001317040.1.
DR   UniGene; Hs.443031; -.
DR   PDB; 3THC; X-ray; 1.80 A; A/B/C/D=24-677.
DR   PDB; 3THD; X-ray; 1.79 A; A/B/C/D=24-677.
DR   PDB; 3WEZ; X-ray; 2.11 A; A/B/C/D=24-677.
DR   PDB; 3WF0; X-ray; 2.20 A; A/B/C/D=24-677.
DR   PDB; 3WF1; X-ray; 2.00 A; A/B/C/D=24-677.
DR   PDB; 3WF2; X-ray; 2.30 A; A/B/C/D=24-677.
DR   PDB; 3WF3; X-ray; 2.15 A; A/B/C/D=24-677.
DR   PDB; 3WF4; X-ray; 2.30 A; A/B/C/D=24-677.
DR   PDBsum; 3THC; -.
DR   PDBsum; 3THD; -.
DR   PDBsum; 3WEZ; -.
DR   PDBsum; 3WF0; -.
DR   PDBsum; 3WF1; -.
DR   PDBsum; 3WF2; -.
DR   PDBsum; 3WF3; -.
DR   PDBsum; 3WF4; -.
DR   ProteinModelPortal; P16278; -.
DR   SMR; P16278; -.
DR   BioGrid; 108984; 39.
DR   IntAct; P16278; 15.
DR   MINT; MINT-3008481; -.
DR   STRING; 9606.ENSP00000306920; -.
DR   BindingDB; P16278; -.
DR   ChEMBL; CHEMBL2522; -.
DR   CAZy; GH35; Glycoside Hydrolase Family 35.
DR   iPTMnet; P16278; -.
DR   PhosphoSitePlus; P16278; -.
DR   SwissPalm; P16278; -.
DR   BioMuta; GLB1; -.
DR   DMDM; 215273939; -.
DR   EPD; P16278; -.
DR   MaxQB; P16278; -.
DR   PaxDb; P16278; -.
DR   PeptideAtlas; P16278; -.
DR   PRIDE; P16278; -.
DR   DNASU; 2720; -.
DR   Ensembl; ENST00000307363; ENSP00000306920; ENSG00000170266.
DR   Ensembl; ENST00000399402; ENSP00000382333; ENSG00000170266.
DR   Ensembl; ENST00000445488; ENSP00000393377; ENSG00000170266.
DR   GeneID; 2720; -.
DR   KEGG; hsa:2720; -.
DR   UCSC; uc003cfh.2; human. [P16278-1]
DR   CTD; 2720; -.
DR   DisGeNET; 2720; -.
DR   GeneCards; GLB1; -.
DR   GeneReviews; GLB1; -.
DR   HGNC; HGNC:4298; GLB1.
DR   HPA; CAB008382; -.
DR   HPA; HPA040610; -.
DR   HPA; HPA069503; -.
DR   MalaCards; GLB1; -.
DR   MIM; 230500; phenotype.
DR   MIM; 230600; phenotype.
DR   MIM; 230650; phenotype.
DR   MIM; 253010; phenotype.
DR   MIM; 611458; gene.
DR   neXtProt; NX_P16278; -.
DR   Orphanet; 79255; GM1 gangliosidosis type 1.
DR   Orphanet; 79256; GM1 gangliosidosis type 2.
DR   Orphanet; 79257; GM1 gangliosidosis type 3.
DR   Orphanet; 309310; Mucopolysaccharidosis type 4B.
DR   PharmGKB; PA28709; -.
DR   eggNOG; KOG0496; Eukaryota.
DR   eggNOG; COG1874; LUCA.
DR   HOGENOM; HOG000221607; -.
DR   HOVERGEN; HBG004841; -.
DR   InParanoid; P16278; -.
DR   KO; K12309; -.
DR   OrthoDB; EOG091G006X; -.
DR   PhylomeDB; P16278; -.
DR   TreeFam; TF314816; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-2022857; Keratan sulfate degradation.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-4085001; Sialic acid metabolism.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; P16278; -.
DR   ChiTaRS; GLB1; human.
DR   GeneWiki; GLB1; -.
DR   GenomeRNAi; 2720; -.
DR   PRO; PR:P16278; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000170266; -.
DR   CleanEx; HS_GLB1; -.
DR   ExpressionAtlas; P16278; baseline and differential.
DR   Genevisible; P16278; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005773; C:vacuole; IBA:GO_Central.
DR   GO; GO:0004565; F:beta-galactosidase activity; IDA:BHF-UCL.
DR   GO; GO:0004308; F:exo-alpha-sialidase activity; TAS:Reactome.
DR   GO; GO:0016936; F:galactoside binding; IEA:Ensembl.
DR   GO; GO:0044262; P:cellular carbohydrate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0019388; P:galactose catabolic process; IEA:Ensembl.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0042340; P:keratan sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   Gene3D; 2.60.120.260; -; 2.
DR   InterPro; IPR026283; B-gal_1-like.
DR   InterPro; IPR025300; BetaGal_jelly_roll_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR031330; Gly_Hdrlase_35_cat.
DR   InterPro; IPR019801; Glyco_hydro_35_CS.
DR   InterPro; IPR001944; Glycoside_Hdrlase_35.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   PANTHER; PTHR23421; PTHR23421; 1.
DR   Pfam; PF13364; BetaGal_dom4_5; 1.
DR   Pfam; PF01301; Glyco_hydro_35; 1.
DR   PIRSF; PIRSF006336; B-gal; 1.
DR   PRINTS; PR00742; GLHYDRLASE35.
DR   SUPFAM; SSF49785; SSF49785; 2.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   PROSITE; PS01182; GLYCOSYL_HYDROL_F35; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Gangliosidosis;
KW   Glycoprotein; Glycosidase; Hydrolase; Lysosome; Mucopolysaccharidosis;
KW   Polymorphism; Reference proteome; Signal; Zymogen.
FT   SIGNAL        1     23
FT   PROPEP       24     28
FT                                /FTId=PRO_0000012185.
FT   CHAIN        29    677       Beta-galactosidase.
FT                                /FTId=PRO_0000012186.
FT   ACT_SITE    188    188       Proton donor. {ECO:0000255}.
FT   ACT_SITE    268    268       Nucleophile. {ECO:0000255}.
FT   CARBOHYD     26     26       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    247    247       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    464    464       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    498    498       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    542    542       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    545    545       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    555    555       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   VAR_SEQ       1     30       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_039974.
FT   VAR_SEQ      83    244       YVPWNFHEPWPGQYQFSEDHDVEYFLRLAHELGLLVILRPG
FT                                PYICAEWEMGGLPAWLLEKESILLRSSDPDYLAAVDKWLGV
FT                                LLPKMKPLLYQNGGPVITVQVENEYGSYFACDFDYLRFLQK
FT                                RFRHHLGDDVVLFTTDGAHKTFLKCGALQGLYTTVDFGT
FT                                -> LPGSCGQVVGSPSAQDEASPLSEWRASYNSA (in
FT                                isoform 2). {ECO:0000303|PubMed:2511208}.
FT                                /FTId=VSP_031241.
FT   VARIANT      10     10       P -> L (in GM1G1; dbSNP:rs7637099).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15791924,
FT                                ECO:0000269|PubMed:2111707,
FT                                ECO:0000269|PubMed:2511208,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_008671.
FT   VARIANT      49     49       R -> C (in GM1G1 and GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:1909089,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_003329.
FT   VARIANT      49     49       R -> H (in GM1G3).
FT                                {ECO:0000269|PubMed:15986423}.
FT                                /FTId=VAR_062340.
FT   VARIANT      51     51       I -> T (in GM1G3).
FT                                {ECO:0000269|PubMed:1907800,
FT                                ECO:0000269|PubMed:1909089}.
FT                                /FTId=VAR_003330.
FT   VARIANT      59     59       R -> C (in GM1G1; loss of galactosidase
FT                                activity; severe mutation).
FT                                {ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_026129.
FT   VARIANT      59     59       R -> H (in GM1G1; with cardiac
FT                                involvement in some patients; loss of
FT                                galactosidase activity; severe mutation).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:17664528,
FT                                ECO:0000269|PubMed:19472408,
FT                                ECO:0000269|Ref.27}.
FT                                /FTId=VAR_008672.
FT   VARIANT      68     68       R -> Q (in GM1G2; 7.4% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062341.
FT   VARIANT      68     68       R -> W (in GM1G2 and GM1G1; loss of
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:12644936,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_026130.
FT   VARIANT      73     73       K -> E (in GM1G3).
FT                                {ECO:0000269|PubMed:15986423}.
FT                                /FTId=VAR_062342.
FT   VARIANT      82     82       T -> M (in GM1G3; mild phenotype).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:19472408,
FT                                ECO:0000269|PubMed:8198123}.
FT                                /FTId=VAR_008673.
FT   VARIANT      83     83       Y -> C (in MPS4B; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_062343.
FT   VARIANT      83     83       Y -> H (in MPS4B; 2-5% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:7586649}.
FT                                /FTId=VAR_008674.
FT   VARIANT     109    109       R -> W (in dbSNP:rs35289681).
FT                                /FTId=VAR_053875.
FT   VARIANT     121    121       R -> S (in GM1G1).
FT                                {ECO:0000269|PubMed:10338095}.
FT                                /FTId=VAR_008675.
FT   VARIANT     123    123       G -> R (in GM1G1; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:1907800,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_003331.
FT   VARIANT     129    129       E -> Q. {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074054.
FT   VARIANT     132    132       M -> T (in GM1G1; 4.3% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062344.
FT   VARIANT     134    134       G -> R (in GM1G2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074055.
FT   VARIANT     134    134       G -> V (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037937.
FT   VARIANT     136    136       P -> S (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062345.
FT   VARIANT     147    147       Missing (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037938.
FT   VARIANT     148    148       R -> C (in GM1G3 and GM1G2).
FT                                {ECO:0000269|PubMed:15986423,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_062346.
FT   VARIANT     148    148       R -> S (in GM1G1).
FT                                {ECO:0000269|PubMed:10839995,
FT                                ECO:0000269|Ref.24}.
FT                                /FTId=VAR_013541.
FT   VARIANT     149    149       S -> F (in MPS4B; 2.0% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062347.
FT   VARIANT     151    151       D -> V (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062348.
FT   VARIANT     151    151       D -> Y (in GM1G1; complete lack of
FT                                protein; loss of galactosidase activity).
FT                                {ECO:0000269|PubMed:15365997,
FT                                ECO:0000269|PubMed:15791924}.
FT                                /FTId=VAR_026131.
FT   VARIANT     155    155       L -> R (in GM1G2 and GM1G3; 6.7% of wild-
FT                                type galactosidase activity).
FT                                {ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_037939.
FT   VARIANT     162    162       L -> S (in GM1G1; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_037940.
FT   VARIANT     173    173       L -> P (in GM1G1; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_062349.
FT   VARIANT     184    184       Q -> R (in GM1G1; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062350.
FT   VARIANT     190    190       G -> D (in GM1G1; 3.4% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062351.
FT   VARIANT     198    198       D -> Y (in MPS4B; 17.4% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062352.
FT   VARIANT     199    199       Y -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062353.
FT   VARIANT     201    201       R -> C (in GM1G1 and GM1G2; 8.4% of wild-
FT                                type galactosidase activity; activity
FT                                severely reduced in transfection with the
FT                                F-436 polymorphism).
FT                                {ECO:0000269|PubMed:12644936,
FT                                ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:1907800,
FT                                ECO:0000269|PubMed:1909089,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_003332.
FT   VARIANT     201    201       R -> H (in GM1G1 and GM1G2; also in a
FT                                patient with a slowly progressive GM1-
FT                                gangliosidosis form; 36.2% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:17664528,
FT                                ECO:0000269|PubMed:19472408,
FT                                ECO:0000269|PubMed:9203065}.
FT                                /FTId=VAR_013542.
FT   VARIANT     208    208       R -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:8213816}.
FT                                /FTId=VAR_008676.
FT   VARIANT     214    214       D -> Y (in GM1G3). {ECO:0000269|Ref.24}.
FT                                /FTId=VAR_013543.
FT   VARIANT     216    216       V -> A (in GM1G1). {ECO:0000269|Ref.24}.
FT                                /FTId=VAR_013544.
FT   VARIANT     236    236       L -> P (in GM1G1; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074056.
FT   VARIANT     239    239       T -> M (in GM1G1; loss of galactosidase
FT                                activity; severe mutation; causes a rapid
FT                                degradation of the protein precursor).
FT                                {ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_026132.
FT   VARIANT     240    240       V -> M (in GM1G1).
FT                                {ECO:0000269|PubMed:10338095}.
FT                                /FTId=VAR_008677.
FT   VARIANT     255    255       Q -> H (in GM1G1; 2.4% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062354.
FT   VARIANT     262    262       G -> E (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074057.
FT   VARIANT     263    263       P -> S (in GM1G3). {ECO:0000269|Ref.26}.
FT                                /FTId=VAR_013545.
FT   VARIANT     264    264       L -> S (in GM1G2).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062355.
FT   VARIANT     266    266       N -> S (in GM1G3).
FT                                {ECO:0000269|PubMed:9203065}.
FT                                /FTId=VAR_013546.
FT   VARIANT     270    270       Y -> D (in GM1G3; originally classified
FT                                as Morquio syndrome).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_013547.
FT   VARIANT     272    272       G -> D (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_038346.
FT   VARIANT     273    273       W -> L (in MPS4B; decreased galactosidase
FT                                activity). {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:1928092,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_003333.
FT   VARIANT     281    281       H -> Y (in GM1G1 and GM1G3).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:15714521}.
FT                                /FTId=VAR_013548.
FT   VARIANT     297    297       L -> F (in GM1G3; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074058.
FT   VARIANT     314    314       F -> L (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074059.
FT   VARIANT     316    316       Y -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:1907800}.
FT                                /FTId=VAR_003334.
FT   VARIANT     318    318       N -> H (in GM1G1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16538002}.
FT                                /FTId=VAR_062356.
FT   VARIANT     329    329       T -> I (in GM1G1; 5.0% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062357.
FT   VARIANT     331    331       Y -> C (in GM1G1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074060.
FT   VARIANT     332    332       D -> E (in GM1G1; 2.3% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062358.
FT   VARIANT     332    332       D -> N (in GM1G1; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:10839995,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_013549.
FT   VARIANT     333    333       Y -> H (in GM1G2; 3.0% of wild-type
FT                                galactosidase activity; the mutant
FT                                protein is localized in the lysosomal-
FT                                endosomal compartment).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062359.
FT   VARIANT     337    337       L -> P (in GM1G1 and GM1G2; loss of
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074061.
FT   VARIANT     346    346       K -> N (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062360.
FT   VARIANT     347    347       Y -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062361.
FT   VARIANT     377    381       Missing (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037941.
FT   VARIANT     397    397       P -> A (in MPS4B; 24.0% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062362.
FT   VARIANT     408    408       Q -> P (in MPS4B; 1.1% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_013550.
FT   VARIANT     414    414       G -> V (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074062.
FT   VARIANT     420    420       T -> K (in GM1G3; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_062363.
FT   VARIANT     420    420       T -> P (in GM1G1; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_062364.
FT   VARIANT     422    422       L -> R (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062365.
FT   VARIANT     434    434       S -> L (in GM1-gangliosidosis;
FT                                unclassified clinical type).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037942.
FT   VARIANT     436    436       L -> F (seems to have a modulating action
FT                                in the expression of the severity of
FT                                other mutations; dbSNP:rs34421970).
FT                                {ECO:0000269|PubMed:12644936,
FT                                ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_026133.
FT   VARIANT     438    438       G -> E (in GM1G3 and MPS4B; mild form;
FT                                5.7% of wild-type galactosidase
FT                                activity). {ECO:0000269|PubMed:12393180,
FT                                ECO:0000269|PubMed:15986423,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_013551.
FT   VARIANT     441    441       D -> N (in GM1G1; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_062366.
FT   VARIANT     442    442       R -> Q (in GM1G1).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062367.
FT   VARIANT     444    444       Y -> C (in MPS4B; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_062368.
FT   VARIANT     457    457       R -> Q (in GM1G3).
FT                                {ECO:0000269|PubMed:1907800}.
FT                                /FTId=VAR_003335.
FT   VARIANT     482    482       R -> C (in MPS4B; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:7586649}.
FT                                /FTId=VAR_008678.
FT   VARIANT     482    482       R -> H (in MPS4B and GM1G1; severe
FT                                decrease in galactosidase activity).
FT                                {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:1487238,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:1928092,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_003336.
FT   VARIANT     484    484       N -> K (in MPS4B; mild form; fibroblasts
FT                                from MPS4B compound heterozygotes for K-
FT                                484 and A-500 have 1.9% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:12393180}.
FT                                /FTId=VAR_013552.
FT   VARIANT     491    491       D -> N (in GM1G1).
FT                                {ECO:0000269|PubMed:10338095}.
FT                                /FTId=VAR_008679.
FT   VARIANT     491    491       D -> Y (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037943.
FT   VARIANT     493    493       K -> N (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074063.
FT   VARIANT     494    494       G -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:1928092}.
FT                                /FTId=VAR_013553.
FT   VARIANT     494    494       G -> S (in MPS4B; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_062369.
FT   VARIANT     500    500       T -> A (in MPS4B; mild form; 2.1% of
FT                                wild-type galactosidase activity).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:12393180,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_013554.
FT   VARIANT     509    509       W -> C (in MPS4B; also in a patient with
FT                                a slowly progressive form of GM1-
FT                                gangisidosis; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:1928092,
FT                                ECO:0000269|PubMed:9203065}.
FT                                /FTId=VAR_003337.
FT   VARIANT     514    514       L -> P (in GM1G1; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074064.
FT   VARIANT     521    521       R -> C (in GM1G1; mild phenotype; unknown
FT                                pathological significance; reduction of
FT                                galactosidase activity; dbSNP:rs4302331).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16641997,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_008680.
FT   VARIANT     532    532       S -> G (polymorphism; results in near-
FT                                normal activity corresponding to 60%-100%
FT                                of the wild-type depending on the
FT                                expression system).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:10839995,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17664528,
FT                                ECO:0000269|Ref.24}.
FT                                /FTId=VAR_008681.
FT   VARIANT     549    549       P -> L (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037944.
FT   VARIANT     554    554       G -> E (in GM1-gangliosidosis;
FT                                unclassified clinical type).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037945.
FT   VARIANT     578    578       K -> R (in GM1G1).
FT                                {ECO:0000269|PubMed:8213816}.
FT                                /FTId=VAR_008682.
FT   VARIANT     579    579       G -> D (in GM1G1 and GM1G2; loss of
FT                                galactosidase activity; severe mutation).
FT                                {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521}.
FT                                /FTId=VAR_013555.
FT   VARIANT     590    590       R -> C (in GM1G1; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:17664528}.
FT                                /FTId=VAR_037946.
FT   VARIANT     590    590       R -> H (in GM1G2).
FT                                {ECO:0000269|PubMed:8213816}.
FT                                /FTId=VAR_008683.
FT   VARIANT     591    591       Y -> C (in GM1G1; with cardiac
FT                                involvement in some patients; loss of
FT                                galactosidase activity; severe mutation;
FT                                causes a rapid degradation of the protein
FT                                precursor). {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|Ref.27}.
FT                                /FTId=VAR_008684.
FT   VARIANT     591    591       Y -> N (in GM1G1; with cardiac
FT                                involvement in some patients; loss of
FT                                galactosidase activity; severe mutation;
FT                                causes a rapid degradation of the protein
FT                                precursor). {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|Ref.27}.
FT                                /FTId=VAR_008685.
FT   VARIANT     595    595       R -> W (reduction of galactosidase
FT                                activity). {ECO:0000269|PubMed:17661814}.
FT                                /FTId=VAR_037947.
FT   VARIANT     597    597       P -> L (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074065.
FT   VARIANT     597    597       P -> S (in GM1G1; 2.1% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062370.
FT   VARIANT     600    600       T -> I (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074066.
FT   VARIANT     632    632       E -> G (in GM1G2).
FT                                {ECO:0000269|PubMed:8213816}.
FT                                /FTId=VAR_008686.
FT   CONFLICT     89     89       H -> Y (in Ref. 4; BAH13196).
FT                                {ECO:0000305}.
FT   CONFLICT    201    201       R -> A (in Ref. 1; AAA51822).
FT                                {ECO:0000305}.
FT   STRAND       32     35       {ECO:0000244|PDB:3THD}.
FT   TURN         36     39       {ECO:0000244|PDB:3THD}.
FT   STRAND       40     43       {ECO:0000244|PDB:3THD}.
FT   STRAND       46     48       {ECO:0000244|PDB:3THD}.
FT   STRAND       51     54       {ECO:0000244|PDB:3THD}.
FT   HELIX        57     59       {ECO:0000244|PDB:3THD}.
FT   HELIX        62     64       {ECO:0000244|PDB:3THD}.
FT   HELIX        65     74       {ECO:0000244|PDB:3THD}.
FT   STRAND       78     83       {ECO:0000244|PDB:3THD}.
FT   HELIX        86     89       {ECO:0000244|PDB:3THD}.
FT   HELIX       100    102       {ECO:0000244|PDB:3THD}.
FT   HELIX       104    113       {ECO:0000244|PDB:3THD}.
FT   STRAND      117    121       {ECO:0000244|PDB:3THD}.
FT   HELIX       131    134       {ECO:0000244|PDB:3THD}.
FT   HELIX       137    141       {ECO:0000244|PDB:3THD}.
FT   STRAND      147    149       {ECO:0000244|PDB:3THD}.
FT   HELIX       152    169       {ECO:0000244|PDB:3THD}.
FT   HELIX       170    172       {ECO:0000244|PDB:3THD}.
FT   HELIX       174    176       {ECO:0000244|PDB:3THD}.
FT   STRAND      178    184       {ECO:0000244|PDB:3THD}.
FT   STRAND      186    188       {ECO:0000244|PDB:3WF0}.
FT   HELIX       189    191       {ECO:0000244|PDB:3THD}.
FT   HELIX       197    211       {ECO:0000244|PDB:3THD}.
FT   STRAND      213    224       {ECO:0000244|PDB:3THD}.
FT   HELIX       225    231       {ECO:0000244|PDB:3THD}.
FT   STRAND      236    241       {ECO:0000244|PDB:3THD}.
FT   HELIX       248    258       {ECO:0000244|PDB:3THD}.
FT   STRAND      260    262       {ECO:0000244|PDB:3THD}.
FT   STRAND      265    272       {ECO:0000244|PDB:3THD}.
FT   HELIX       286    298       {ECO:0000244|PDB:3THD}.
FT   STRAND      302    306       {ECO:0000244|PDB:3THD}.
FT   TURN        322    324       {ECO:0000244|PDB:3THD}.
FT   HELIX       345    354       {ECO:0000244|PDB:3THD}.
FT   TURN        355    357       {ECO:0000244|PDB:3THD}.
FT   STRAND      375    378       {ECO:0000244|PDB:3THD}.
FT   STRAND      380    384       {ECO:0000244|PDB:3THD}.
FT   TURN        385    388       {ECO:0000244|PDB:3THD}.
FT   HELIX       389    392       {ECO:0000244|PDB:3THD}.
FT   STRAND      398    402       {ECO:0000244|PDB:3THD}.
FT   HELIX       407    409       {ECO:0000244|PDB:3THD}.
FT   STRAND      413    421       {ECO:0000244|PDB:3THD}.
FT   STRAND      426    433       {ECO:0000244|PDB:3THD}.
FT   STRAND      439    447       {ECO:0000244|PDB:3THD}.
FT   STRAND      450    456       {ECO:0000244|PDB:3THD}.
FT   TURN        457    459       {ECO:0000244|PDB:3THD}.
FT   STRAND      462    467       {ECO:0000244|PDB:3THD}.
FT   STRAND      472    478       {ECO:0000244|PDB:3THD}.
FT   HELIX       487    489       {ECO:0000244|PDB:3THD}.
FT   STRAND      509    513       {ECO:0000244|PDB:3THD}.
FT   HELIX       516    521       {ECO:0000244|PDB:3THD}.
FT   TURN        522    527       {ECO:0000244|PDB:3THD}.
FT   STRAND      550    556       {ECO:0000244|PDB:3THD}.
FT   STRAND      568    572       {ECO:0000244|PDB:3THD}.
FT   STRAND      578    583       {ECO:0000244|PDB:3THD}.
FT   STRAND      586    591       {ECO:0000244|PDB:3THD}.
FT   TURN        593    595       {ECO:0000244|PDB:3THD}.
FT   STRAND      601    603       {ECO:0000244|PDB:3THD}.
FT   HELIX       605    607       {ECO:0000244|PDB:3THD}.
FT   STRAND      610    612       {ECO:0000244|PDB:3THD}.
FT   STRAND      614    622       {ECO:0000244|PDB:3THD}.
FT   STRAND      627    629       {ECO:0000244|PDB:3THD}.
FT   HELIX       631    633       {ECO:0000244|PDB:3THD}.
FT   STRAND      634    641       {ECO:0000244|PDB:3THD}.
SQ   SEQUENCE   677 AA;  76075 MW;  74421586B1BCFECA CRC64;
     MPGFLVRILP LLLVLLLLGP TRGLRNATQR MFEIDYSRDS FLKDGQPFRY ISGSIHYSRV
     PRFYWKDRLL KMKMAGLNAI QTYVPWNFHE PWPGQYQFSE DHDVEYFLRL AHELGLLVIL
     RPGPYICAEW EMGGLPAWLL EKESILLRSS DPDYLAAVDK WLGVLLPKMK PLLYQNGGPV
     ITVQVENEYG SYFACDFDYL RFLQKRFRHH LGDDVVLFTT DGAHKTFLKC GALQGLYTTV
     DFGTGSNITD AFLSQRKCEP KGPLINSEFY TGWLDHWGQP HSTIKTEAVA SSLYDILARG
     ASVNLYMFIG GTNFAYWNGA NSPYAAQPTS YDYDAPLSEA GDLTEKYFAL RNIIQKFEKV
     PEGPIPPSTP KFAYGKVTLE KLKTVGAALD ILCPSGPIKS LYPLTFIQVK QHYGFVLYRT
     TLPQDCSNPA PLSSPLNGVH DRAYVAVDGI PQGVLERNNV ITLNITGKAG ATLDLLVENM
     GRVNYGAYIN DFKGLVSNLT LSSNILTDWT IFPLDTEDAV RSHLGGWGHR DSGHHDEAWA
     HNSSNYTLPA FYMGNFSIPS GIPDLPQDTF IQFPGWTKGQ VWINGFNLGR YWPARGPQLT
     LFVPQHILMT SAPNTITVLE LEWAPCSSDD PELCAVTFVD RPVIGSSVTY DHPSKPVEKR
     LMPPPPQKNK DSWLDHV
//
